Michael Ashford

Michael Ashford

Bispecific-Antibody-Pipeline-Insights

Bispecific Antibody Pipeline Drugs and Companies Insight Report, 2025: Clinical, Commercial, and Developmental Analysis

(Las Vegas, Nevada, United States) According to DelveInsight’s latest evaluation, the global bispecific antibody pipeline includes more than 180 active companies collectively developing over 250 bispecific antibody–based therapeutic candidates. The pipeline analysis provides a detailed overview of clinical trials, therapeutic approaches, mechanisms
4 February 2026